Drugs fail to meet hormone targets in control of rare growth disorder
Over a quarter of UK patients treated for growth hormone-producing tumours do not achieve 'safe' growth hormone (GH) levels, according to a 30 year UK multi-centre study of clinical management of the rare disease acromegaly. ...
Oct 10, 2013
0
0